The Daily Biotech Pulse: AzurRx Jumps On Data, Agios’ Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 17)
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 16)
2 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
3 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
6 Stocks Moving In Monday’s After-Hours Session
Gainers
Cerecor (NASDAQ: CERC) shares are trading higher after the company announced initial Phase 1b results for CERC-002 in moderate to severe Crohn's Disease patients.
Agile Therapeutics: Q2 Earnings Insights
Shares of Agile Therapeutics (NASDAQ:AGRX) rose in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share fell 66.67% year over year to ($0.20), which beat the estimate of ($0.21).
Agile Therapeutics Q2 EPS $(0.20) Beats $(0.21) Estimate; Total Prescriptions Up 171%
Agile Therapeutics (NASDAQ:AGRX) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.21) by 4.76 percent. This is a 66.67 percent decrease over losses of $(0.12) per share from